Myra E Van Linde

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8098656/publications.pdf

Version: 2024-02-01

		1163117	996975
16	480	8	15
papers	citations	h-index	g-index
16	16	16	805
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial. Lancet Oncology, The, 2022, 23, 53-64.	10.7	165
2	Tumor Drug Concentration and Phosphoproteomic Profiles After Two Weeks of Treatment With Sunitinib in Patients with Newly Diagnosed Glioblastoma. Clinical Cancer Research, 2022, 28, 1595-1602.	7.0	12
3	Efficacy of the eHealth application Oncokompas, facilitating incurably ill cancer patients to self-manage their palliative care needs: A randomized controlled trial. Lancet Regional Health - Europe, The, 2022, 18, 100390.	5.6	9
4	Metoclopramide, Dexamethasone, or Palonosetron for Prevention of Delayed Chemotherapy-Induced Nausea and Vomiting After Moderately Emetogenic Chemotherapy (MEDEA): A Randomized, Phase III, Noninferiority Trial. Oncologist, 2021, 26, e173-e181.	3.7	7
5	Smartphone measurements of physical activity and fitness are associated with early trial discontinuation of patients in (hemato)oncology phase I/II clinical trials. Supportive Care in Cancer, 2021, 29, 3783-3792.	2.2	2
6	Abstract CT025: Dabrafenib plus trametinib in BRAF V600E-mutant high-grade (HGG) and low-grade glioma (LGG). , 2021, , .		5
7	Clinical judgment of the need for professional mental health care in patients with cancer: a qualitative study among oncologists and nurses. Journal of Cancer Survivorship, 2021, , 1.	2.9	1
8	The Current Status of Immune Checkpoint Inhibitors in Neuro-Oncology: A Systematic Review. Cancers, 2020, 12, 586.	3.7	48
9	Clinical assessment of emotions in patients with cancer: Diagnostic accuracy compared with two reference standards. Psycho-Oncology, 2020, 29, 775-780.	2.3	4
10	Data-driven prioritization and preclinical evaluation of therapeutic targets in glioblastoma. Neuro-Oncology Advances, 2020, 2, vdaa151.	0.7	1
11	Clinical management of emotions in patients with cancer: introducing the approach "emotional support and case findingâ€. Translational Behavioral Medicine, 2020, 10, 1399-1405.	2.4	8
12	Efficacy and cost-utility of the eHealth application $\hat{a}\in \Omega$ ncokompas $\hat{a}\in M$, supporting patients with incurable cancer in finding optimal palliative care, tailored to their quality of life and personal preferences: a study protocol of a randomized controlled trial. BMC Palliative Care, 2019, 18, 85.	1.8	13
13	Distress in patients with cancer $\hat{a} \in \hat{a}$ on the need to distinguish between adaptive and maladaptive emotional responses. Acta Oncol \tilde{A}^3 gica, 2017, 56, 1026-1029.	1.8	36
14	Treatment outcome of patients with recurrent glioblastoma multiforme: a retrospective multicenter analysis. Journal of Neuro-Oncology, 2017, 135, 183-192.	2.9	138
15	Evaluation of potential circulating biomarkers for prediction of response to chemoradiation in patients with glioblastoma. Journal of Neuro-Oncology, 2016, 129, 221-230.	2.9	13
16	Bevacizumab in Combination With Radiotherapy and Temozolomide for Patients With Newly Diagnosed Glioblastoma Multiforme. Oncologist, 2015, 20, 107-108.	3.7	18